These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 17179211)

  • 1. Mutations in the connection domain of HIV-1 reverse transcriptase increase 3'-azido-3'-deoxythymidine resistance.
    Nikolenko GN; Delviks-Frankenberry KA; Palmer S; Maldarelli F; Fivash MJ; Coffin JM; Pathak VK
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):317-22. PubMed ID: 17179211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in human immunodeficiency virus type 1 RNase H primer grip enhance 3'-azido-3'-deoxythymidine resistance.
    Delviks-Frankenberry KA; Nikolenko GN; Barr R; Pathak VK
    J Virol; 2007 Jul; 81(13):6837-45. PubMed ID: 17428874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3'-azido-3'-deoxythymidine through both RNase H-dependent and -independent mechanisms.
    Ehteshami M; Beilhartz GL; Scarth BJ; Tchesnokov EP; McCormick S; Wynhoven B; Harrigan PR; Götte M
    J Biol Chem; 2008 Aug; 283(32):22222-32. PubMed ID: 18547911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.
    Gupta S; Fransen S; Paxinos EE; Stawiski E; Huang W; Petropoulos CJ
    Antimicrob Agents Chemother; 2010 May; 54(5):1973-80. PubMed ID: 20194692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision.
    Delviks-Frankenberry KA; Nikolenko GN; Boyer PL; Hughes SH; Coffin JM; Jere A; Pathak VK
    Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10943-8. PubMed ID: 18667707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
    J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanism by which the K70E mutation in human immunodeficiency virus type 1 reverse transcriptase confers resistance to nucleoside reverse transcriptase inhibitors.
    Sluis-Cremer N; Sheen CW; Zelina S; Torres PS; Parikh UM; Mellors JW
    Antimicrob Agents Chemother; 2007 Jan; 51(1):48-53. PubMed ID: 17088490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-specific differences in the human immunodeficiency virus type 1 reverse transcriptase connection subdomain of CRF01_AE are associated with higher levels of resistance to 3'-azido-3'-deoxythymidine.
    Delviks-Frankenberry KA; Nikolenko GN; Maldarelli F; Hase S; Takebe Y; Pathak VK
    J Virol; 2009 Sep; 83(17):8502-13. PubMed ID: 19553318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.
    Brehm JH; Scott Y; Koontz DL; Perry S; Hammer S; Katzenstein D; Mellors JW; Sluis-Cremer N;
    PLoS One; 2012; 7(2):e31558. PubMed ID: 22363673
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amino acid residues in HIV-2 reverse transcriptase that restrict the development of nucleoside analogue resistance through the excision pathway.
    Álvarez M; Nevot M; Mendieta J; Martínez MA; Menéndez-Arias L
    J Biol Chem; 2018 Feb; 293(7):2247-2259. PubMed ID: 29275329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.
    Delviks-Frankenberry KA; Lengruber RB; Santos AF; Silveira JM; Soares MA; Kearney MF; Maldarelli F; Pathak VK
    Virology; 2013 Jan; 435(2):433-41. PubMed ID: 23068886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The L74V mutation in human immunodeficiency virus type 1 reverse transcriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations.
    Miranda LR; Götte M; Liang F; Kuritzkes DR
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2648-56. PubMed ID: 15980332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase.
    Boyer PL; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2001 May; 75(10):4832-42. PubMed ID: 11312355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors.
    Menéndez-Arias L; Betancor G; Matamoros T
    Antiviral Res; 2011 Nov; 92(2):139-49. PubMed ID: 21896288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
    Kisic M; Mendieta J; Puertas MC; Parera M; Martínez MA; Martinez-Picado J; Menéndez-Arias L
    J Mol Biol; 2008 Oct; 382(2):327-41. PubMed ID: 18662701
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequency.
    Nikolenko GN; Svarovskaia ES; Delviks KA; Pathak VK
    J Virol; 2004 Aug; 78(16):8761-70. PubMed ID: 15280484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.
    Lengruber RB; Delviks-Frankenberry KA; Nikolenko GN; Baumann J; Santos AF; Pathak VK; Soares MA
    J Antimicrob Chemother; 2011 Apr; 66(4):702-8. PubMed ID: 21393163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-steady-state kinetic characterization of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance.
    Kerr SG; Anderson KS
    Biochemistry; 1997 Nov; 36(46):14064-70. PubMed ID: 9369478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.